A Registry for People With T-cell Lymphoma

Inclusion Criteria:

• Written informed consent

• Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.

• Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting oneof the following diagnostic criterion (based on WHO classification and NCCNguidelines):

• T-cell prolymphocytic leukemia

• T-cell large granular lymphocytic leukemia

• Chronic lymphoproliferative disorder of NK cells

• Aggressive NK-cell leukemia

• Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood

• Chronic active EBV infection of T- and NK-cell type, systemic form

• Hydroa vacciniforme-like lymphoproliferative disorder

• Adult T-cell leukemia/lymphoma

• Extranodal NK/T-cell lymphoma, nasal type

• Enteropathy-associated T-cell lymphoma

• Monomorphic epitheliotropic intestinal T-cell lymphoma

• Intestinal T-cell lymphoma, not otherwise specified (NOS)

• Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract

• Hepatosplenic T-cell lymphoma

• Subcutaneous panniculitis-like T-cell lymphoma

• Mycosis fungoides (limited to those with ≥ stage IB disease and those receivingactive therapy)

• Sézary syndrome

• Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)

• Primary cutaneous Gamma-Delta T-cell lymphoma

• Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma

• Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)

• Peripheral T-cell lymphoma, not otherwise specified

• Angioimmunoblastic T-cell lymphoma

• Follicular T-cell lymphoma

• Nodal peripheral T-cell lymphoma with TFH phenotype

• Anaplastic large cell lymphoma, ALK-positive

• Anaplastic large cell lymphoma, ALK-negative

• Breast-implant associated anaplastic large cell lymphoma.

• NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplasticlarge cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must bereceiving systemic therapy.

Exclusion Criteria:

• Patients with of mycosis fungoides, primary cutaneous anaplastic large celllymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemictherapy.

• Inability to collect prospective data, measure response, or perform adequatefollow-up assessments in the clinical judgment of the treating physician. NOTE:Repository participation does not exclude participation in clinical trials, nor doesexisting clinical trial participation exclude enrollment in the study hereinoutlined.